tiprankstipranks
Open Orphan Plc (GB:HVO)
LSE:HVO
UK Market
HVO
Open Orphan Plc
RESEARCH TOOLSreports
Want to see GB:HVO full AI Analyst Report?

Open Orphan Plc (HVO) Earnings Dates, Call Summary & Reports

35 Followers

Earnings Data

Report Date
Sep 15, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
―
Last Year’s EPS
<0.01
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Apr 15, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call balanced notable strategic and operational progress (diversification, acquisitions integrated, expanded lab and clinical capabilities, unique HCT models, renewed contracts and pipeline growth) against material financial headwinds in 2025 (significant cash depletion, order book reduction, cancellations, and margin pressure from non-HCT work). Management delivered a small profit, reiterated confidence in near-term pipeline (Traws Pharma) and longer-term pivot (ILiAD Phase III, guidance for high single-digit growth in 2026), but the company faces near-term liquidity and booking visibility challenges as it executes the diversification strategy.
Company Guidance
Guidance from the call highlighted that after a challenging FY2025 (revenue £46.8m; profit £1.4m despite net acquisition losses of £1.4m), the company finished the year with £14.3m cash (down from £44.2m) after using ~£29m of cash (core £15.4m, inorganic £14.5m), generating £10.4m from operations and spending £1.4m on PPE; the order book was restated to £30m (from £43.5m) under a stricter CTA-based recognition policy (SUA→CTA lag 5–12 months). Management expects HCT’s share of revenue to fall from >85% in 2024 to under 50% in 2025 (i.e., >50% non-HCT going forward), sees a 50% increase in new proposals in Q1 2026 YoY, has signed the Traws Pharma HCT (up to 150 subjects, majority of revenue in 2026) and is near-finalizing a multiyear ILiAD Phase III whooping cough HCT (majority revenue in 2027), and forecasts high single‑digit revenue growth in 2026; other metrics cited include ongoing Phase I wins typically £0.6–1.0m each, Cryostore revenue £0.8m, German clinical trials £12.3m, variable cost rates roughly 15% for HCT and 25–30% for clinical trials, ~200 beds, and a 350,000-strong volunteer database.
Full-year Revenue and Profitability
Reported revenue of GBP 46.8m for FY2025 and an operating profit of GBP 1.4m despite headwinds and net acquisition losses of GBP 1.4m, demonstrating underlying profitability in a challenging year.
Strategic Diversification and Rebranding
Completed integration and rebrand under the single hVIVO brand, consolidating services into four service lines (consulting, clinical trials, human challenge trials, laboratory) to offer an end-to-end drug development platform and reduce reliance on HCT alone.
Expansion into Phase I and Broader Clinical Capabilities
Successfully expanded into Phase I work and now offers Phase I–III capabilities, enabling cross-selling (Phase I + HCT combinations) and access to a broader client base across preclinical to Phase III development.
New Commercial Human Challenge Models
Launched contemporary influenza challenge models and the world's only commercial hMPV challenge model, strengthening the company's differentiated HCT offering.
Notable New Contracts and Pipeline Momentum
Announced a new influenza prophylactic antiviral HCT contract (Traws Pharma) with majority of revenue expected in 2026; near-finalization of the multi‑year ILiAD Phase III whooping cough HCT (major revenues expected in 2027).
Acquisitions Delivered and Integrated
Acquisitions completed and integrated: Cryostore (revenue GBP 0.8m; high margin; 90–95% retention) and German clinical research units (revenue GBP 12.3m); group-wide systems and line management realigned.
Laboratory Capability Upgrades
Invested in new lab equipment including Europe’s first digital droplet PCR (Hamilton) and NGS capability to bring previously outsourced services in-house, improving speed, margins and service scope.
Pipeline and Business Development Traction
New proposals up ~50% year-on-year in Q1 2026 and continuing signing of Phase I contracts (~GBP 0.6–1.0m each); guidance for high single-digit revenue growth in 2026 indicates expected recovery.

Open Orphan Plc (GB:HVO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

GB:HVO Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 15, 2026
2026 (Q2)
- / -
0.003―――
Apr 15, 2026
2025 (Q4)
- / >-0.01
0.008-212.50% (-0.02)――
Sep 23, 2025
2025 (Q2)
- / <0.01
0.008-62.50% (>-0.01)――
Apr 10, 2025
2024 (Q4)
- / <0.01
0.018-55.56% (>-0.01)――
Sep 10, 2024
2024 (Q2)
- / <0.01
0.00633.33% (<+0.01)――
Apr 09, 2024
2023 (Q4)
<0.01 / 0.02
-0.0021000.00% (+0.02)――
Sep 12, 2023
2023 (Q2)
- / <0.01
0―――
Apr 25, 2023
2022 (Q4)
- / >-0.01
-0.0020.00% (0.00)――
Sep 08, 2022
2022 (Q2)
- / 0.00
0.002―――
Jun 07, 2022
2021 (Q4)
- / >-0.01
-0.00666.67% (<+0.01)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:HVO Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 15, 2026
8.70 p8.45 p-2.87%
Sep 23, 2025
9.00 p8.30 p-7.78%
Apr 10, 2025
14.44 p14.83 p+2.74%
Sep 10, 2024
28.38 p29.17 p+2.79%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Open Orphan Plc (GB:HVO) report earnings?
Open Orphan Plc (GB:HVO) is schdueled to report earning on Sep 15, 2026, Before Open (Confirmed).
    What is Open Orphan Plc (GB:HVO) earnings time?
    Open Orphan Plc (GB:HVO) earnings time is at Sep 15, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Open Orphan Plc stock?
          The P/E ratio of Open Orphan Plc is N/A.
            What is GB:HVO EPS forecast?
            Currently, no data Available